Modifying tumor-associated macrophages: An important adjunct to immunotherapy

The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fridlender, Zvi G, Albelda, Steven M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902117/
https://www.ncbi.nlm.nih.gov/pubmed/24498549
http://dx.doi.org/10.4161/onci.26620
_version_ 1782300949018050560
author Fridlender, Zvi G
Albelda, Steven M
author_facet Fridlender, Zvi G
Albelda, Steven M
author_sort Fridlender, Zvi G
collection PubMed
description The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.
format Online
Article
Text
id pubmed-3902117
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39021172014-02-04 Modifying tumor-associated macrophages: An important adjunct to immunotherapy Fridlender, Zvi G Albelda, Steven M Oncoimmunology Author's View The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials. Landes Bioscience 2013-12-01 2013-10-21 /pmc/articles/PMC3902117/ /pubmed/24498549 http://dx.doi.org/10.4161/onci.26620 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Fridlender, Zvi G
Albelda, Steven M
Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title_full Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title_fullStr Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title_full_unstemmed Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title_short Modifying tumor-associated macrophages: An important adjunct to immunotherapy
title_sort modifying tumor-associated macrophages: an important adjunct to immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902117/
https://www.ncbi.nlm.nih.gov/pubmed/24498549
http://dx.doi.org/10.4161/onci.26620
work_keys_str_mv AT fridlenderzvig modifyingtumorassociatedmacrophagesanimportantadjuncttoimmunotherapy
AT albeldastevenm modifyingtumorassociatedmacrophagesanimportantadjuncttoimmunotherapy

Ejemplares similares